Guardant Health (NASDAQ:GH) reported strong quarterly revenue of $301.67 million, a 48.3% increase year-over-year, surpassing analyst estimates.
Growth was driven by a 36% increase in oncology revenue and a significant jump in screening revenue to nearly $42.00 million.
Despite an improved loss per share of $0.45 and strong short-term liquidity (current ratio of 4.68), Guardant Health remains unprofitable with a negative earnings yield of -3.58%.
Guardant Health (NASDAQ:GH) is a company focused on precision oncology. It develops blood tests, known as liquid biopsies, to detect cancer early and help guide treatment. The company operates in a competitive field, aiming to provide non-invasive alternatives to traditional tissue biopsies for cancer screening and monitoring.
On May 7, 2026, Guardant Health reported strong quarterly revenue of $301.67 million. This represents a 48.3% increase from the same period last year. The figure also surpassed the Zacks Consensus Estimate. According to Zacks Investment Research, this is the fourth straight quarter the company has exceeded revenue expectations.
The revenue growth comes from two main areas. Oncology revenue increased by 36% to $205.00 million. Screening revenue saw a very large jump to nearly $42.00 million from $5.70 million a year ago. Following this performance, Guardant Health increased its revenue guidance for 2026, as highlighted by Business Wire.
The company reported a loss per share of $0.45. This is an improvement from the loss of $0.49 per share a year ago and better than the estimated loss of $0.47. Despite growing revenue, Guardant Health is not yet profitable, which is reflected in its negative earnings yield of -3.58%.
Guardant Health shows strong short-term financial health with a current ratio of 4.68. This means its current assets are over four times its short-term liabilities. However, its debt-to-equity ratio is -9.26, indicating negative shareholder equity, which can occur in companies that are heavily investing in growth.
